Photo from Unsplash
Originally Posted On: https://bluefinvision.com/blog/what-chinas-high-volume-cataract-centres-reveal-about-surgical-standards-and-what-it-means-for-patients-in-the-uk/
Mr Mfazo Hove, Consultant Ophthalmic Surgeon and Founder of Blue Fin Vision®, has been invited to collaborate with leading ophthalmic centres in China to discuss modern cataract surgery, trifocal lens technology, and patient outcomes. This post explains what prompted that invitation, what the collaboration involves, and, most importantly, what patients in the United Kingdom can take from it.
China’s premium ophthalmic centres operate at surgical volumes that most UK practices will never approach. That volume creates a form of clinical insight that cannot be manufactured in a lower-throughput environment: the patterns become visible only when you have seen enough cases. How different patient populations respond to trifocal IOLs across age ranges. How neuroadaptation timelines vary with occupation and visual demand. Where refractive surprises cluster, and what pre-operative variables predict them. These are the conversations Mr Mfazo Hove has been invited to participate in, and to contribute to from his own independently audited outcome data.
Blue Fin Vision®’s posterior capsule rupture rate is approximately 0.2% against a national UK benchmark of 1.01% across 961,208 operations.¹ Mr Hove submits to National Ophthalmology Database audit across four consecutive years. That data is the currency of the conversation – a validated, externally benchmarked outcome series that meets the standard these centres apply.
Why High-Volume Centres Matter, and What They Can Teach
There is a class of clinical knowledge that only emerges at scale. Individual centres with annual cataract volumes in the tens of thousands accumulate pattern recognition – across IOL platforms, patient demographics, biometric edge cases, and complication management – that a lower-volume practice can take decades to develop independently. International collaboration is, in part, a mechanism for compressing that timeline.
As a ZEISS Key Opinion Leader, Mr Hove will present at both the ZEISS APAC User Meeting in Shanghai and the ZEISS EMEA User Meeting in Istanbul within weeks of each other. The most valuable exchange at meetings of this kind is not about surgical technique – phacoemulsification is well-standardised at this level. It is about systems: how pre-operative counselling is structured when patients arrive with different baseline expectations; how enhancement planning is handled when a large proportion of patients receive premium IOLs; how complication management is organised in high-throughput environments without sacrificing the quality of individual patient care.
These are system-design questions. They are the questions that separate practices that produce consistently excellent outcomes from those that produce excellent outcomes most of the time. Mr Mfazo Hove’s interest in this collaboration is specifically that dimension – what the systems architecture looks like at scale, and what elements are transferable to Blue Fin Vision®’s model.
The Trifocal Lens Conversation
A significant part of the planned discussions concerns trifocal intraocular lenses – their real-world performance, the patient populations best suited to them, and how centres that implant large volumes manage the post-operative experience.
Mr Mfazo Hove has had bilateral ZEISS AT LISA tri 839MP trifocal lenses implanted in his own eyes. He is simultaneously the surgeon who recommends this procedure and the patient who has lived its recovery for two years. That combination – personal clinical conviction verified by two years of lived experience – shapes every lens replacement consultation he conducts. It also means that the conversations he will have with Chinese colleagues carry a specificity that a surgeon without personal experience of the lens cannot offer: not what the literature predicts, but what the neuroadaptation process actually feels like, and where the counselling conversation most needs to be strengthened.
The clinical case for trifocal IOLs in appropriately selected patients is well-established. Prospective studies confirm 96% spectacle independence and uncorrected distance visual acuity of 0.1 logMAR or better in 91% of eyes.² ³ But the outcome literature consistently identifies that patient satisfaction variance is predicted less by the optical quality of the implant than by the accuracy of patient selection, the completeness of pre-operative counselling, and the quality of post-operative support.⁴ Patients often tell Mr Hove that previous consultations elsewhere did not address the neuroadaptation timeline, the expected photic phenomena in the first weeks, or what the realistic range of outcomes looks like. Those omissions are what produce dissatisfied patients from technically successful surgeries. These are the conversations Mr Hove will be having in China.
Patients considering trifocal lenses can read more here.
This level of pre-operative rigour – dual biometry, post-refractive formula selection, structured neuroadaptation counselling, and individually disclosed outcome data benchmarked against the national NOD standard – is not yet standard in many UK private ophthalmic practices. At Blue Fin Vision® it is the baseline.
What Accurate Measurement Makes Possible
One area where the collaboration is particularly relevant to patient outcomes is biometric accuracy and IOL power calculation. Modern optical biometers achieve exceptional axial length precision, but refractive predictability – the closeness of the achieved refraction to the planned target – depends on the formula applied, the quality of pre-operative data, and the recognition of cases where standard formulas underperform.
Post-refractive corneas are the most clinically demanding biometric scenario in routine cataract surgery. Standard IOL formulas systematically underestimate the power required in eyes that have undergone previous laser surgery, leading to hyperopic refractive surprise if the calculation is not adjusted. Mr Mfazo Hove uses specific post-refractive formulas for these cases as standard, and dual biometry – measuring every eye on two independent devices before surgery – is part of every Blue Fin Vision® pre-operative assessment. Recent work on IOL formula accuracy demonstrates that newer generation formulas outperform older ones substantially in post-refractive eyes, though no formula yet eliminates the need for experienced clinical judgement.⁵
In practice, this means something very simple: the refractive outcome is decided at the pre-operative assessment, not in theatre.
The operation can be technically flawless and the visual outcome still disappointing if the pre-operative measurement was inadequate or the wrong formula was applied. This is the systems principle that Mr Hove will be exploring with colleagues in China, where the pre-operative pathway in high-volume settings has been refined across patient numbers that few Western practices can match.
What Shared Decision-Making Looks Like in Practice
Across international ophthalmic settings, the research on shared decision-making in cataract and refractive surgery consistently identifies the same barriers: patients lack sufficient disease knowledge before the consultation, clinicians face time constraints, and the information provided does not always map onto what patients actually need to know to make a good decision for themselves.⁶
Mr Mfazo Hove’s consultation model at Blue Fin Vision® is structured specifically around those barriers. Lens selection is treated as a shared decision – not a clinical recommendation that the patient accepts, but a conversation in which the patient’s visual priorities, occupation, tolerance for photic phenomena, and attitude toward glasses all inform the outcome. Mr Hove shows patients his own outcome data before consent. He names the national PCR benchmark alongside his own figures. He describes the neuroadaptation timeline for premium lenses not from the literature but from personal experience.
In high-volume Chinese centres, this level of individualised consultation has been adapted for larger patient cohorts through structured pre-consultation education pathways that prepare patients before they meet the surgeon. That adaptation – retaining the quality of informed decision-making while accommodating higher throughput – is one of the most directly applicable insights Mr Hove expects to bring back to Blue Fin Vision®.
Read more about cataract surgery or lens replacement.
What This Means for Blue Fin Vision® Patients
For patients at Blue Fin Vision®, the direct relevance of this collaboration is not abstract. It feeds into the precision of lens selection, the quality of pre-operative counselling, the rigour of biometric protocols, and the structure of post-operative support. Every improvement in how Mr Mfazo Hove understands trifocal IOL outcomes across large patient populations translates into more accurate conversations in consultation – a better-calibrated description of what to expect, a sharper identification of which patients are and are not good candidates, and a more refined enhancement protocol for the small proportion of patients whose refractive outcome falls outside the target range.
The principle underlying Blue Fin Vision®’s approach – to achieve the immeasurable, you must measure everything – is not a British invention. It is a global clinical standard that the most serious surgical centres apply regardless of geography. Mr Mfazo Hove’s participation in this collaboration is an expression of that same standard: seeking out the settings where measurement is most rigorous, learning what the data shows, and bringing it back into the practice where it will directly benefit the patients who sit across the desk.
This is what continuous improvement looks like in practice at Blue Fin Vision® – not a quality promise, but a structured commitment to learning from the best centres in the world.
Mr Mfazo Hove’s four consecutive years of independently audited outcome data, including PCR rate benchmarked against the national NOD standard, are available here.
Looking Forward
Modern cataract surgery continues to evolve – in IOL design, in biometric precision, in refractive planning for complex eyes. But the advances that most directly determine whether a patient leaves surgery satisfied are not technological. They are found in the quality of decision-making before surgery, the clarity of communication during it, and the integrity of the systems that surround both.
Mr Mfazo Hove will share further insights from this collaboration on his return. The conversation about what world-class cataract and lens replacement surgery looks like is one he intends to conduct openly – because patients who are deciding where to have surgery that will affect their vision for the rest of their lives deserve access to the same level of information that surgeons share with each other.
References
- Day AC, Donachie PHJ, Sparrow JM, Johnston RL. The Royal College of Ophthalmologists’ National Ophthalmology Database study of cataract surgery: report 17, a risk factor model for posterior capsule rupture. Eye. 2024; doi: 10.1038/s41433-024-03262-z. PMID: 39294232
- Mojzis P, Pena-Garcia P, Liehneova I, Ziak P, Pinero DP. Outcomes of a new diffractive trifocal intraocular lens. J Cataract Refract Surg. 2014;40:60-69. PMID: 24269200
- Kohnen T, Titke C, Bohm M. Trifocal intraocular lens implantation to treat visual demands in various distances following lens removal: 6-month results of a prospective study. Am J Ophthalmol. 2016;166:161-168. PMID: 27109340
- Gundersen KG, Potvin R. Comparative visual performance with monofocal and multifocal intraocular lenses. Clin Ophthalmol. 2013;7:1979-1985. PMID: 24143072
- Kane JX, Van Heerden A, Atik A, Petsoglou C. Accuracy of intraocular lens power formulas. J Cataract Refract Surg. 2017;43:333-339. PMID: 28285845
- Bouaziz M, Cheng T, Minuti A, Denisova K, Barmettler A. Shared decision making in ophthalmology: A scoping review. Am J Ophthalmol. 2022;237:146-153. PMID: 34942109
ABOUT THE AUTHOR
Mr Mfazo Hove
Consultant Ophthalmic Surgeon
MBChB MD FRCOphth CertLRS
Mr Hove is a consultant ophthalmic surgeon who has performed more than 57,000 procedures. His training includes 6.5 years of specialist development at Moorfields Eye Hospital, followed by five years as a consultant at the Western Eye Hospital (Imperial College Healthcare NHS Trust). He is a consultant at Blue Fin Vision®, an elite ophthalmology clinic serving London, Essex and Hertfordshire, working alongside an experienced clinical team delivering comprehensive ophthalmic care. He specialises in cataract surgery and advanced vision correction, including laser procedures, lens replacement and implantable Collamer lenses (ICL).
Schedule Your Consultation Today
If you are considering cataract surgery, lens replacement, or trifocal lenses, book a consultation with Mr Mfazo Hove and the Blue Fin Vision® team to discuss your options.
With consultant-led care, independently audited outcomes, and locations across London, Hertfordshire, and Essex, your decision will be guided by the same data and clinical rigour described in this article.
